MAZE - NASDAQ

Maze Therapeutics, Inc.

MAZE·NASDAQ

$25.06

+3.2%

HealthcareBiotechnology

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.39B

EPS-3.0500

P/E Ratio-8.22

Earnings Date08/11/2026

397.13M

Assets

65%

3Y+165.0%

5Y+165.0%

10Y+165.0%

42.16M

Total Liabilities

-3%

3Y-13.0%

5Y-13.0%

10Y-13.0%

354.97M

Total Equity

80%

3Y+250.0%

5Y+250.0%

10Y+250.0%

Maze Therapeutics, Inc. Funding & Solvency Profile

MAZE · NASDAQ

Current Assets

Cash & Cash Equivalents189.25M

Net Receivables1.50M

Inventory0.00

Other Current Assets6.30M

Total Current Assets350 M

Non-Current Assets

Property, Plant & Equipment25.16M

Goodwill & Intangible Assets0.00

Long-Term Investments19.20M

Other Non-Current Assets3.05M

Total Non-Current Assets47 M

Total Assets

397.13M

Financial Health Analysis

Current Ratio

15.50x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.12x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

327 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

88% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Maze Therapeutics, Inc. Balance Sheet

MAZE • NASDAQ

Maze Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	189.2M	196.8M	29.2M	99.9M
Short-Term Investments	152.7M	0.0	0.0	0.0
Cash & Short-Term Investments	341.9M	196.8M	29.2M	99.9M
Net Receivables	1.5M	0.0	0.0	0.0
Other Receivables	1.5M	0.0	0.0	0.0
Other Current Assets	6.3M	4.9M	5M	6.2M
Total Current Assets	349.7M	201.7M	34.1M	106.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	25.2M	29.9M	35M	41.2M
Long-Term Investments	19.2M	1.1M	1.1M	1.2M
Other Non-Current Assets	3M	7.9M	1.3M	1.4M
Total Non-Current Assets	47.4M	38.9M	37.4M	43.8M
Total Assets	397.1M	240.5M	71.5M	150M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.8M	1.9M	2M	1.6M
Accounts Payable	1.8M	1.9M	2M	1.6M
Accrued Expenses	0.0	8.1M	6.9M	7.4M
Capital Lease Obligations (Current)	4.8M	4.6M	4.5M	4.3M
Other Current Liabilities	16M	6M	2.9M	7.5M
Total Current Liabilities	22.6M	20.7M	16.3M	20.8M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	20.1M	0.0
Other Non-Current Liabilities	1.1M	969K	0.0	0.0
Total Non-Current Liabilities	19.6M	23M	45.1M	27.7M
Capital Lease Obligations	23.3M	26.6M	29.5M	32.1M
Total Liabilities	42.2M	43.6M	61.5M	48.5M
SHAREHOLDERS' EQUITY
Preferred Stock	397.1M	508.1M	383.9M	383.9M
Common Stock	49K	2K	22K	21K
Additional Paid-In Capital	844.4M	47.2M	21.8M	12.8M
Retained Earnings	-489.5M	-358.4M	-395.7M	-295.3M
Accumulated Other Comprehensive Income/Loss	110K	0.0	0.0	0.0
Total Stockholders' Equity	355M	196.9M	10.1M	101.4M
Total Equity	355M	196.9M	10.1M	101.4M
SUMMARY
Total Liabilities & Equity	397.1M	240.5M	71.5M	150M
Total Investments	171.9M	1.1M	1.1M	1.2M
Total Debt	23.3M	26.6M	49.6M	32.1M
Net Debt	-165.9M	-170.2M	20.5M	-67.9M
Shares Outstanding	48,076,885	48,076,885	48,076,885	48,076,885

SEC Filings

MAZE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 22, 2026	May 18, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 22, 2026	April 21, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 25, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 04, 2026	February 02, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 23 filings

Related Guides

Blog Categories

Continue your MAZE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.